Sana Biotechnology News

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer

Flagship Pioneering and ProFound Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a...

PR NewswireJun 12 07:00 ET

GFS, PETS and CYTK Are Among After Hour Movers

Seeking AlphaMay 22 17:10 ET

Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington's Disease and Other...

Globe NewswireMay 21 09:00 ET

Bank of America Securities Remains a Buy on Sana Biotechnology (SANA)

TipRanksMay 13 11:05 ET

Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results

Yahoo FinanceMay 10 13:35 ET

Express News | HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target

BenzingaMay 9 15:22 ET

Sana Biotechnology Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 61.18% HC Wainwright & Co. → $12 Reiterates Buy → Buy 03/01/2024 101.48% JMP Securities $8 → $1

BenzingaMay 9 15:21 ET

Express News | Sana Biotechnology Shares Are Trading Lower After the Company Reported Q1 Financial Results

BenzingaMay 9 13:53 ET

Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs

Seeking AlphaMay 9 13:22 ET

Sana Biotechnology: Promising Clinical Studies and Breakthrough Potential in T1D Therapy

TipRanksMay 9 06:36 ET

Buy Rating Affirmed for Sana Biotechnology Amidst Strong Clinical Progress and Solid Financials

TipRanksMay 9 01:15 ET

Sana Biotechnology Q1 Adj $(0.32), Inline

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 25.58 percent increase over losses of $(0.43) per share from the sam

BenzingaMay 8 17:23 ET

Sana Biotechnology | 10-Q: Quarterly report

SEC announcementMay 8 17:04 ET · Announcements

Express News | Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

ReutersMay 8 16:05 ET

Express News | Sana Biotechnology Q1 Adjusted EPS USD -0.32 Vs. Ibes Estimate USD -0.32

ReutersMay 8 16:05 ET

Express News | Sana Biotechnology Q1 Net Income USD -107.475 Million

ReutersMay 8 16:05 ET

Express News | Sana Biotechnology Q1 Adjusted Net Income USD -69.468 Million Vs. Ibes Estimate USD -69.6 Million

ReutersMay 8 16:05 ET

Express News | Sana Biotechnology Q1 Operating Expenses USD 110.724 Million

ReutersMay 8 16:05 ET

Press Release: Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmu

Dow JonesMay 8 16:05 ET

Sana Biotechnology to Present at May and June 2024 Investor Conferences

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations

GlobeNewswireMay 6 16:05 ET